Presently, only a small number of lung cancer cases are
spotted in the relatively treatable first stage of the disease – less than 20%.
Now, what if a non-invasive, cost-effective early detection screening method
were developed? It will likely offer noticeable improvements in survival rates
and decreases in mortality rates. This is where Zenosense comes in.
Zenosense, an emergent healthcare technology company, has
taken on the challenge of developing functioning yet cost-effective medical
devices that will detect, early on, deadly bacteria and certain cancers in a
patient’s exhaled breath. One of the devices under development at the company
is a device intended to detect lung cancer – and there has been quite a bit of
activity surrounding the device’s development lately.
In November, Zenosense announced plans to manufacture a
pre-market prototype device that would ultimately be evaluated during a lung
cancer detection trial in a clinical setting. Zenon Biosystem, Zenosense’s
contracted development partner, took on the task of manufacturing the
prototype. In preparation for the planned trial and to meet the standards of
the trial’s protocol design, Zenon planned to manufacture two pre-commercial
devices of identical design to ensure that trial results could be duplicated.
A month later, in December 2014, Zenon announced that it
would be collaborating with a university and a large university hospital in
Madrid, Spain on a nine month long lung cancer detection trial that will
facilitate clinical tests on breath samples from 400 people; this is also in
line with the protocol design that was previously announced.
The Zenosense team believes that a cost-effective,
breath-analyzing lung cancer detector that is proven to meet or exceed the
accuracy of low-dose Computed Tomography (CT) scanning will have broad appeal
and demand. As a result, the team has eagerly welcomed the news that a group of
university research scientists and the university hospital have recognized the
potential for their technology. A positive outcome from the planned lung cancer
detection trial will be a significant step toward a major healthcare
breakthrough.
For more information, visit www.zenosense.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment